Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals Inc. | P2B001 | Early-stage Parkinson's disease (PD) | Phase 3 | Data Released | oral | Neurology |
| Hepion Pharmaceuticals Inc. | Rencofilstat - (ALTITUDE-NASH) | Non-alcoholic steatohepatitis (NASH) | Phase 2 | Data Released | Oral | Gastroenterology |
| Hepion Pharmaceuticals Inc. | Rencofilstat | Nonalcoholic steatohepatitis (NASH) F3 subjects | Phase 2b | Oral | Gastroenterology | |
| HOOKIPA Pharma Inc. | HB-200 with pembrolizumab - (Investigator Lead Trial) | HPV16+ Squamous cell head and neck cancers (HNSCC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| HOOKIPA Pharma Inc. | Eseba-vec (HB-200) - (AVALON-1) | HPV16+ oropharyngeal squamous cell carcinoma (OPSCC) | Phase 2/3 | Trial Planned | Intravenous | Oncology |
| HOOKIPA Pharma Inc. | HB-101 | Cytomegalovirus (CMV) | Phase 2 | Ongoing | intranasal | Antiviral |
| HOOKIPA Pharma Inc. | Eseba-vec (formerly HB-200) in combination with KEYTRUDA (pembrolizumab) | Head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Data Released | Intravenous | Oncology |
| Hoth Therapeutics Inc. | HT-001 - (CLEER-001) | EGFRI-induced skin toxicity | Phase 2a | Data Released | Topical | Oncology |
